CAS: 30186-18-6; 1-(4-Bromo-2-Hydroxyphenyl)Ethanone

上下游产品

CAS号35065-86-2 3-溴乙酸苯酯 | CAS号591-20-8 3-溴苯酚 | CAS号108-24-7 乙酸酐 | CAS号75-16-1 甲基溴化镁 | CAS号288067-35-6 4-溴-2-羟基苯甲腈 | CAS号2398-37-0 间溴苯甲醚 | CAS号75-36-5 乙酰氯 | CAS号2142-63-4 3-溴代苯乙酮 | CAS号161386-22-7 4'-[5-fluoro-3-... | CAS号1095544-88-9 1-(4-bromo-2-hy... | CAS号18735-82-5 7-溴-4-羟基-2H-色烯-2-酮 | CAS号690632-38-3 叔-丁基 6-溴-4-羰基螺[... | CAS号72135-36-5 2-甲氧基-4-溴苯甲酸 | CAS号66033-69-0 6-溴-3-甲基苯并噁唑 | CAS号130200-01-0 7-溴-2,2-二甲基苯并吡喃-4-酮 | CAS号1369594-48-8 5-Bromo-2-(5-ch... | CAS号168759-60-2 7-溴-4H-色烯-4-酮 | CAS号18442-22-3 7-溴-4-二氢色原酮 | CAS号113850-96-7 7-溴-4-氧亚基-4H-色烯-2-羧酸

间溴苯酚置于吡啶,Aluminum (Iii) Chloride体系中,用 二氯甲烷 作为反应溶剂,化学反应生成 4-溴-2-羟基苯乙酮
参考文献:发现有效的大环 Hcv Ns5A 抑制剂
标题:发现有效的大环 Hcv Ns5A 抑制剂
摘要:Hcv Ns5A 抑制剂已在 Hcv 复制子测定中显示出令人印象深刻的体外病毒学特征,并在临床上显着降低 Hcv Rna 滴度,使其成为治疗 Hcv 感染的全口服固定剂量组合 (Fdc) 方案中具有吸引力的成分.默克公司在这一领域的努力将 Mk-4882 和 Mk-8325 确定为早期的开发线索.在此,我们描述了具有 Mk-8325 或 Mk-4882 核心结构的强效大环 Ns5A 抑制剂的发现.
DOI:10.1016/j.Bmcl.2016.05.042

专利信息

专利号:US-2022356182-A1
优先权日:2009-03-27
标题 :Inhibitors of hepatitis c virus replication
发明人：COBURN CRAIG A; LUDMERER STEVEN W; LIU KUN; WU HAO; SOLL RICHARD; ZHONG BIN; ZHU JIAN
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-11053243-B2
优先权日:2009-03-27
标 题:Inhibitors of hepatitis C virus replication
发明人：COBURN CRAIG A; LUDMERER STEVEN W; LIU KUN; WU HAO; SOIL RICHARD; ZHONG BIN; ZHU JIAN
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-9090661-B2
优先权日:2009-03-27
标 题:Inhibitors of hepatitis C virus replication
发明人：COBURN CRAIG A; MCCAULEY JOHN A; LUDMERER STEVEN W; LIU KUN; VACCA JOSEPH P; WU HAO; HU BIN; SOLL RICHARD; SUN FEI; WANG XINGHAI; YAN MAN; ZHANG CHENGREN; ZHENG MINGWEI; ZHONG BIN; ZHU JIAN
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:CN-116515782-A
优先权日:2022-01-24
标题:A mutant of amine dehydrogenase and its application in the synthesis of chiral aminoalcohol compounds

专利号:US-8129411-B2
优先权日:2005-12-30
标题:Organic compounds
发明人：EHARA TAKERU; GROSCHE PHILIPP; IRIE OSAMU; IWAKI YUKI; KANAZAWA TAKANORI; KAWAKAMI SHIMPEI; KONISHI KAZUHIDE; MOGI MUNETO; SUZUKI MASAKI; YOKOKAWA FUMIAKI
权利人:EHARA TAKERU; GROSCHE PHILIPP; IRIE OSAMU; IWAKI YUKI; KANAZAWA TAKANORI; KAWAKAMI SHIMPEI; KONISHI KAZUHIDE; MOGI MUNETO; SUZUKI MASAKI; YOKOKAWA FUMIAKI; NOVARTIS AG
摘要:The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. n The compounds have the formula I′ n nwherein R1, R2, T, R3 and R4 are as defined in the specification.

专利号:US-8178559-B2
优先权日:2004-12-30
标 题:Organic compounds
发明人：BREITENSTEIN WERNER; EHARA TAKERU; EHRHARDT CLAUS; GROSCHE PHILIPP; HITOMI YUKO; IWAKI YUKI; KANAZAWA TAKANORI; KONISHI KAZUHIDE; MAIBAUM JUERGEN KLAUS; MASUYA KEIICHI; IWASAKI ATSUKO; OSTERMANN NILS; SUZUKI MASAKI; TOYAO ATSUSHI; YOKOKAWA FUMIAKI
权利人:BREITENSTEIN WERNER; EHARA TAKERU; EHRHARDT CLAUS; GROSCHE PHILIPP; HITOMI YUKO; IWAKI YUKI; KANAZAWA TAKANORI; KONISHI KAZUHIDE; MAIBAUM JUERGEN KLAUS; MASUYA KEIICHI; IWASAKI ATSUKO; OSTERMANN NILS; SUZUKI MASAKI; TOYAO ATSUSHI; YOKOKAWA FUMIAKI; NOVARTIS AG
摘要:3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.